stockrow
Monday 9 November 2026
Export NUVOQ’s income statement to Excel — free account
Holdco Nuvo Group D.G Ltd.
NUVOQHoldco Nuvo Group D.G Ltd.’s revenue for fiscal 2023 (year ended December 2023) was $176,000.00.
0.00
0.00
NaN
Follow NUVOQ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | (8.52) | — | ||||||
| EBT | — | — | — | — | — | — | — | (34) | (20) | (35) | +0.9% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (19,712.50) | (19,712.5) pt | ||||||
| Net income | — | — | — | 0 | — | — | — | (35) | (21) | (34) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (2.03) | (1.21) | (1.86) | (4.3%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (0.85) | (0.79) | (0.83) | (1.0%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.01) | (0.01) | 0.00 | (61.3%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (0.86) | (0.81) | (0.83) | (1.7%) | ||||||
| Book value | — | — | — | — | — | — | — | (0.51) | (2.27) | (3.74) | +171.0% | ||||||
| Shares, m | — | — | — | — | — | — | — | 17 | 17 | 18 | +3.1% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (0.74) | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (14) | (13) | (15) | +2.1% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | (60.0%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (15) | (14) | (15) | +1.4% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 1 | (39) | (29) | n/m | |||||
| Net debt | — | — | — | — | — | — | — | (1) | 8 | 11 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (9) | (39) | (67) | +179.5% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | (13.15) | (15.54) | (930.47) | (917.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | (28.67) | 87.36 | 63.38 | +92.1 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 3 | 3 | 59 | +343.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · fundamentals updated 26 Oct 2026
Holdco Nuvo Group D.G Ltd. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AIDX 20/20 Biolabs Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | −23.98% (below 0%: shrinking) | 41.71% | (170.30%) | Compare |
| IVF INVO Fertility, Inc | $2.6M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NUWE Nuwellis, Inc. | $2.5M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.3M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | |
| ADGM Adagio Medical Holdings, Inc. | $1.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GCTK GlucoTrack, Inc. | $1.7M | — (loss-making) | — (loss-making) | +342.48% (above 0%: growing) | n/m | +3.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $2.5M | — | — | +8.05% | — | +3.65% | 33.72% | (110.11%) |